Synergy Biomedical, a privately-held medical device company, is all set to unveil its BioSphere Putty, the next generation Bioactive bone graft product that received FDA approval recently.
Composed of 45S5 bioactive glass spheres that are combined with a moldable phospholipid carrier, BioSphere Putty provides excellent handling, and is resistant to irrigation, said the company.
The spherical shape in the Putty is claimed to offer uniform and repeatable resorption and ion release. Additionally, the 3-D packing of the spheres in a bone defect makes an optimal porosity that permits bone formation all over the implant.
Synergy Biomedical CEO and founder Dr. Mark Borden said, "The use of spherical particles has allowed Synergy to identify an optimal form of bioactive glass that improves bone formation."